ReviewNature reviews. Urology2011
Male late-onset hypogonadism: pathogenesis, diagnosis and treatment.
Review in Nature reviews. Urology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Discovery of novel ancestry specific genes for androgens and hypogonadism in Million Veteran Program Men.Nature communications · 2025Pooled it
- Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.Journal of endocrinological investigation · 2015Pooled it
- Efficacy and Safety of TESTOPEAKAmerican journal of men's healthTrial
- Successful sexual aging: A narrative review using the multidimensional theoretical paradigm of systems sexology to explore sexual health in midlife and older adults.Journal of endocrinological investigation · 2026Review
- Testosterone replacement therapy and spermatogenesis in reproductive age men.Nature reviews. Urology · 2025Review
- Mechanisms of Leydig Cell Aging and Obesity-Related Hypogonadism in Men: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Association between serum cotinine and total testosterone in adult males based on NHANES 2011-2016.Scientific reports · 2024Article
- Single-cell transcriptome profiling highlights the importance of telocyte, kallikrein genes, and alternative splicing in mouse testes aging.Scientific reports · 2024Article
- Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Rescue Testicular Aging.Biomedicines · 2024Article
- Regulation of retinoid mediated StAR transcription and steroidogenesis in hippocampal neuronal cells: Implications for StAR in protecting Alzheimer's disease.Biochimica et biophysica acta. Molecular basis of disease · 2023Article
- The Effect of a Combination ofNutrients · 2022Article
- Prevalence and Reasons for the Absence of Vaginal Intercourse in Chinese Middle-Aged and Elderly Men.Sexual medicine · 2022Article
- In Vitro Differentiation of Leydig Cells From hiPSCs: A First Step Towards a Cellular Therapy for Hypogonadism?Endocrinology · 2022Article
- Effects of larval extracts from identifiedFood science & nutrition · 2021Article
- Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy.Current urology · 2021Article
- Associations between smoking, sex hormone levels and late-onset hypogonadism in men differ depending on age.Aging · 2021Article
- Testosterone Deficiency Is a Risk Factor for Severe COVID-19.Frontiers in endocrinology · 2021Article
- Article
- Conversion of Fibroblast into Functional Leydig-like Cell Using Defined Small Molecules.Stem cell reports · 2020Article
- Lipid accumulation product and late-onset hypogonadism in middle-aged and elderly men: results from a cross-sectional study in China.BMJ open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some aging men develop a condition of suppressed serum testosterone levels, which is associated with diffuse sexual, physical and psychological symptoms. Several terms are used for this syndrome, but late-onset hypogonadism (LOH) is preferred. The diagnosis of LOH is often uncertain because symptoms (occurring in 20-40% of men) and low circulating testosterone (found in 20% of men >70 years of age) seldom occur together. The strict diagnostic criteria for LOH include reproducibly low serum testosterone levels and sexual symptoms, including erectile dysfunction and reduced frequency of sexual thoughts and morning erections. Using these diagnostic criteria, only 2% of 40-80-year-old men have LOH. Obesity and impaired general health (including diabetes mellitus, cardiovascular and chronic obstructive pulmonary disease, and frailty) are more common reasons for low testosterone than advanced age per se. It seems logical, therefore, to begin by treating these conditions before testosterone replacement therapy is initiated. Even then, testosterone should only be used if there are no contraindications, such as unstable cardiac disease, serious prostate symptoms and high hemoglobin level. The long-term benefit of testosterone replacement therapy is uncertain, and the experimental nature of the treatment, and its associated risks, must be fully explained to the patient before treatment begins.
Indexed as
Identifiers
21502974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.